Deep learning for prediction of isocitrate dehydrogenase mutation in gliomas: a critical approach, systematic review and meta-analysis of the diagnostic test performance using a Bayesian approach
- PMID: 35919062
- PMCID: PMC9338374
- DOI: 10.21037/qims-22-34
Deep learning for prediction of isocitrate dehydrogenase mutation in gliomas: a critical approach, systematic review and meta-analysis of the diagnostic test performance using a Bayesian approach
Abstract
Background: Conventionally, identifying isocitrate dehydrogenase (IDH) mutation in gliomas is based on histopathological analysis of tissue specimens acquired via stereotactic biopsy or definitive resection. Accurate pre-treatment prediction of IDH mutation status using magnetic resonance imaging (MRI) can guide clinical decision-making. We aim to evaluate the diagnostic performance of deep learning (DL) to determine IDH mutation status in gliomas.
Methods: A systematic search of Cochrane Library, Web of Science, Medline, and Scopus was conducted to identify relevant publications until August 1, 2021. Articles were included if all the following criteria were met: (I) patients with histopathologically confirmed World Health Organization (WHO) grade II, III, or IV gliomas; (II) histopathological examination with the IDH mutation; (III) DL was used to predict the IDH mutation status; (IV) sufficient data for reconstruction of confusion matrices in terms of the diagnostic performance of the DL algorithms; and (V) original research articles. Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and Checklist for Artificial Intelligence in Medical Imaging (CLAIM) was used to assess the studies' quality. Bayes theorem was utilized to calculate the posttest probability.
Results: Four studies with a total of 1,295 patients were included. In the training set, the pooled sensitivity, specificity, and area under the summary receiver operating characteristic (SROC) curve were 93.9%, 90.9% and 0.958, respectively. In the validation set, the pooled sensitivity, specificity, and area under the SROC curve were 90.8%, 85.5% and 0.939, respectively. With a known pretest probability of 80.2%, the Bayes theorem yielded a posttest probability of 97.6% and 96.0% for a positive test and 27.0% and 30.6% for a negative test for training sets and validation sets, respectively.
Discussion: This is the first meta-analysis that summarizes the diagnostic performance of DL in predicting IDH mutation status in gliomas via the Bayes theorem. DL algorithms demonstrate excellent diagnostic performance in predicting IDH mutation in gliomas. Radiomic features associated with IDH mutation, and its underlying pathophysiology extracted from advanced MRI may improve prediction probability. However, more studies are required to optimize and increase its reliability. Limitations include obtaining some data via email and lack of training and test sets statistics.
Keywords: Deep learning (DL); gliomas; isocitrate dehydrogenase (IDH); magnetic resonance imaging (MRI); radiomics.
2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-22-34/coif). The authors have no conflicts of interest to declare.
Figures








Similar articles
-
Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.Eur Radiol. 2020 Aug;30(8):4664-4674. doi: 10.1007/s00330-020-06717-9. Epub 2020 Mar 19. Eur Radiol. 2020. PMID: 32193643 Review.
-
The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.Neurosurg Focus. 2019 Dec 1;47(6):E13. doi: 10.3171/2019.9.FOCUS19660. Neurosurg Focus. 2019. PMID: 31786548
-
Diagnostic accuracy of a machine learning-based radiomics approach of MR in predicting IDH mutations in glioma patients: a systematic review and meta-analysis.Front Oncol. 2024 Jul 30;14:1409760. doi: 10.3389/fonc.2024.1409760. eCollection 2024. Front Oncol. 2024. PMID: 39139289 Free PMC article.
-
Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review.AJNR Am J Neuroradiol. 2021 Jan;42(1):94-101. doi: 10.3174/ajnr.A6875. Epub 2020 Nov 26. AJNR Am J Neuroradiol. 2021. PMID: 33243896 Free PMC article.
-
Comparison of MRI Sequences to Predict IDH Mutation Status in Gliomas Using Radiomics-Based Machine Learning.Biomedicines. 2024 Mar 25;12(4):725. doi: 10.3390/biomedicines12040725. Biomedicines. 2024. PMID: 38672080 Free PMC article.
Cited by
-
MRI-derived deep learning models for predicting 1p/19q codeletion status in glioma patients: a systematic review and meta-analysis of diagnostic test accuracy studies.Neuroradiology. 2025 May 15. doi: 10.1007/s00234-025-03631-z. Online ahead of print. Neuroradiology. 2025. PMID: 40369298 Review.
-
Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH-Mutant Glioma.AJNR Am J Neuroradiol. 2025 Jan 8;46(1):113-120. doi: 10.3174/ajnr.A8413. AJNR Am J Neuroradiol. 2025. PMID: 38997123
-
Enhancing hospital course and outcome prediction in patients with traumatic brain injury: A machine learning study.Neuroradiol J. 2024 Feb;37(1):74-83. doi: 10.1177/19714009231212364. Epub 2023 Nov 3. Neuroradiol J. 2024. PMID: 37921691 Free PMC article.
-
Predicting IDH and ATRX mutations in gliomas from radiomic features with machine learning: a systematic review and meta-analysis.Front Radiol. 2024 Oct 31;4:1493824. doi: 10.3389/fradi.2024.1493824. eCollection 2024. Front Radiol. 2024. PMID: 39544481 Free PMC article.
-
Predicting IDH Mutation in Glioma Patients Using Deep Learning Algorithms with Conformal Prediction.J Imaging Inform Med. 2025 Jun 25. doi: 10.1007/s10278-025-01580-w. Online ahead of print. J Imaging Inform Med. 2025. PMID: 40563037
References
-
- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73. 10.1056/NEJMoa0808710 - DOI - PMC - PubMed
-
- Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18. 10.1007/s00401-010-0781-z - DOI - PubMed
-
- Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560-6. 10.1212/WNL.0b013e3181f96282 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous